erythromycin lactobionate

Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.[1] It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).[2] Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.[3],[4] Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.[5],[6]

Erythromycin (E-Mycin) is a Macrolide and Macrolide Antimicrobial. The physiologic effect of erythromycin is by means of Decreased Sebaceous Gland Activity.

Erythromycin-13C-d3 is a 13C- and deuterated erythromycin that can be used to study the metabolic pathways of erythromycin in vivo.

Erythromycin hydrochloride is an inhibitor of protein translation and mammalian mRNA splicing. It inhibits growth of gram negative and gram positiove bacteria.

Erythromycin estolate is a semi-synthetic derivative of erythromycin with good oral absorption and bioavailability tolerance. As a macrolide antibiotic, Erythromycin exerts its antibacterial action by inhibiting bacterial protein synthesis and is mainly used in studies for the treatment of respiratory, skin and soft tissue infections caused by susceptible bacteria. Erythromycin estolate may cause liver injury, including mild cholestatic hepatitis, jaundice, and paucity of bile ducts.

Erythromycin Gluceptate is an inhibitor of protein translation and mammalian mRNA splicing. It inhibits growth of gram negative and gram positiove bacteria.